Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Coronavirus (2019-nCoV)
CHENGDU, China – 28 January 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that it has initiated development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus that is believed to have originated from Wuhan, China. Since this… Read More